| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/14/2002 | US20020032329 Method for the preparation of tetrahydrobenzothiepines |
| 03/14/2002 | US20020032324 Process for the preparation of endotoxin-free or endotoxin-depleted nucleic acids and/or oligonucleotides for gene therapy |
| 03/14/2002 | US20020032306 Cyclopeptide derivatives |
| 03/14/2002 | US20020032234 First fatty acid compound that is a linoleic or linolenic compound and a second fatty acid that is a docosahexaenoic acid compound, an omega-3 or an omega-2 fatty acid or derivative |
| 03/14/2002 | US20020032226 Amorphous 5-(4-aminosulfonyl-3-fluorophenyl)-4-cyclohexyl-2-methyloxazole compound, free of crystals; improved water solubility; treatment of COX-2 mediated disorders. |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020032221 Treatment of HIV mediated diseases. |
| 03/14/2002 | US20020032219 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 03/14/2002 | US20020032217 Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
| 03/14/2002 | US20020032210 Chloride channel blockers; useful in the treatment of sickle cell anaemia, brain edema following iscaemia or tumors, diarrhea, hypertension, bone metabolic disorders, osteoclast associated disoders; substituted biphenyl containing nitrogen |
| 03/14/2002 | US20020032208 Chemical compounds |
| 03/14/2002 | US20020032207 2-Cyclohexyl quinazoline NMDA/NR2B antagonists |
| 03/14/2002 | US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor |
| 03/14/2002 | US20020032202 Administering a pharmaceutically effective dose of the heterocycle-containing carboxylic acid derivative or salt to a patient suffering form acute promyelocytic leukemia |
| 03/14/2002 | US20020032199 5-HT7 receptor antagonists |
| 03/14/2002 | US20020032196 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032194 CRF receptor antagonists and methods relating thereto |
| 03/14/2002 | US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors |
| 03/14/2002 | US20020032183 Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as JNK-inhibitors |
| 03/14/2002 | US20020032181 For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated |
| 03/14/2002 | US20020032179 Inhibiting the hyperproliferation of malignant or neoplastic cells by treating the cells with an antiproliferative amount of 1 alpha ,24(S)-dihydroxyvitamin D2 the cells being cancers of the lung, neck and head, pancreas, endometrium, bladder |
| 03/14/2002 | US20020032174 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 03/14/2002 | US20020032170 Underivatized, aqueous soluble beta (1-3) glucan, composition and method of making same |
| 03/14/2002 | US20020032157 Methods of inhibiting ectopic calcification |
| 03/14/2002 | US20020032156 Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders |
| 03/14/2002 | US20020032151 Using an agent which promotes tyrosine protein dephosphorylation in the preparation of a medicament for reducing permeability of a physiological barrier such as the blood-brain barrier |
| 03/14/2002 | US20020031831 Plasmid for use in vaccination and gene therapy |
| 03/14/2002 | US20020031800 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | US20020031793 Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
| 03/14/2002 | US20020031792 Complexing with monoclonal antibodies |
| 03/14/2002 | US20020031529 Neurotoxin therapy for diabetes |
| 03/14/2002 | US20020031524 Polysaccharide and complexes contain glucose and any of galactose, rhamnose, mannose, arabinose, n-acetyl glucosamine and n-acetyl galactosamine; increase proliferation of splenocytes and cytokine production; immunomodulators |
| 03/14/2002 | US20020031517 Administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta superfamily of structurally-related growth factors |
| 03/14/2002 | US20020031515 Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| 03/14/2002 | US20020031514 Method for induction of differentiation of osteoclasts |
| 03/14/2002 | US20020031512 Inhibiting immunological activation of keratinocytes by administering molecule that binds to CD40 but does not activate CD40-expressing keratinocytes |
| 03/14/2002 | US20020031510 Contacting B7-positive cell with first soluble ligand which recognizes and binds B7 antigen, and contacting gp39-positive cell with second soluble ligand which recognizes and binds gp39 antigen; inhibiting rejection of transplanted tissues |
| 03/14/2002 | US20020031508 Administering inducer of P-selectin activity such that hemostasis occurs |
| 03/14/2002 | US20020031505 Antitumor compositions containing taxane derivatives |
| 03/14/2002 | US20020031480 Aerosolizing a hydrofluoroalkane (HFA)/THC composition to provide droplets respirable by a lung of a patient, and administering; inhalers; treating pain, cachexia, migraines, nausea,muscle spasticity |
| 03/14/2002 | DE10043667A1 2-Guanidino-4-aryl-chinazoline 2-guanidino-4-aryl-quinazolines |
| 03/14/2002 | DE10043227A1 Neuartiges entwicklungsbiologisches Gen Novel biological developmental gene |
| 03/14/2002 | DE10043124A1 Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase Method for the diagnosis of neural disorders and for the treatment of primary hemostasis deficiency |
| 03/14/2002 | DE10042997A1 Thienopyrimidine Thienopyrimidines |
| 03/14/2002 | DE10042655A1 Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion Process for the preparation of inhibitors of cell adhesion |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2422198A1 Substituted hydrazine derivatives |
| 03/14/2002 | CA2422159A1 Novel polymorphic form of 17-beta-(n-ter.butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it |
| 03/14/2002 | CA2422157A1 Inhibitors of serine protease activity of matriptase or mtsp1 |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421872A1 Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant |
| 03/14/2002 | CA2421834A1 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | CA2421783A1 Receptor in the edb fibronectin domain |
| 03/14/2002 | CA2421760A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421757A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421510A1 A method for treating allergies using substituted pyrazoles |
| 03/14/2002 | CA2421506A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | CA2421502A1 A method for treating allergies |
| 03/14/2002 | CA2421493A1 A method for treating allergies using substituted pyrazoles |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421218A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421172A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | CA2421075A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421070A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | CA2421027A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421018A1 Dihydroxy open-acid salt of simvastatin |
| 03/14/2002 | CA2420890A1 Antithrombotic compositions |
| 03/14/2002 | CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | CA2419983A1 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure |
| 03/14/2002 | CA2419979A1 Mammalian genes; related reagents and methods |
| 03/14/2002 | CA2419590A1 Exemestane as chemopreventing agent |
| 03/14/2002 | CA2419563A1 Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides |
| 03/14/2002 | CA2419456A1 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | CA2417594A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors |
| 03/14/2002 | CA2416336A1 Multivalent neuraminidase inhibitor conjugates |
| 03/14/2002 | CA2412279A1 "pseudo"-native chemical ligation |
| 03/14/2002 | CA2412278A1 Polymer-modified synthetic proteins |
| 03/14/2002 | CA2412277A1 Synthetic erythropoiesis stimulating proteins |
| 03/14/2002 | CA2389739A1 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same |
| 03/14/2002 | CA2389602A1 Methods and compositions for potentiating cancer chemotherapeutic agents |
| 03/13/2002 | EP1186672A2 Polymorphisms in the human organic anion transporter C (OATP-C) gene |
| 03/13/2002 | EP1186604A1 Benzazepine derivatives, process for the preparation of the same and uses thereof |
| 03/13/2002 | EP1186603A2 Processes for preparing endothelin antagonists |
| 03/13/2002 | EP1186594A1 N-alkoxyalkyl-n,n-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same |
| 03/13/2002 | EP1186318A2 Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist |
| 03/13/2002 | EP1186303A2 Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| 03/13/2002 | EP1185862A2 Method and compositions relating to insulin resistance disorders |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185674A1 Cationic lipids for gene transfer and preparation method thereof |
| 03/13/2002 | EP1185655A1 Equine granulocyte-macrophage colony-stimulating factor (gm-csf) |
| 03/13/2002 | EP1185652A2 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 03/13/2002 | EP1185649A2 The myostatin gene promoter and inhibition of activation thereof |
| 03/13/2002 | EP1185632A1 Caspase-8 crystals, models and methods |
| 03/13/2002 | EP1185559A2 Compositions and methods for cancer treatment by selectively inhibiting vegf |